The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy
Lan Zhang, Mengshu You, Bin Yan, Jian Zhang, Yi Yao, Qingyan Zhang, Zuozhong Xie, Shixiang Wang, Qian Gao · 2026
Read The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy by Lan Zhang, Mengshu You, Bin Yan, Jian Zhang, Yi Yao, Qingyan Zhang, Zuozhong Xie, Shixiang Wang, Qian Gao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13597369.txt.
Description
Lan Zhang and colleagues report a 2026 study of a protein called SPA17 in melanoma. The protein normally appears only in sperm production, but many cancers switch it back on. Its role in melanoma was largely unknown. The team measured it in patient tissue and tested what it does in cells and mice.
SPA17 was much higher in melanoma than in healthy tissue, and highest in tumors that had spread. Patients with more of it fared worse and responded less well to immune therapy. Turning the protein down slowed cancer cell growth and movement. The team traced its effect through a partner protein, AXL, known to drive aggressive tumors. A vaccine aimed at SPA17 also fought tumors in mice. The findings mark the protein as both a warning sign and a possible treatment target.
Catalog record
| CREATOR | Lan Zhang, Mengshu You, Bin Yan, Jian Zhang, Yi Yao, Qingyan Zhang, Zuozhong Xie, Shixiang Wang, Qian Gao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |